Accounts Payable	9 Months Ended
Sep. 30, 2023
Accounts Payable [Abstract]
Accounts Payable	5. Accounts Payable As of September 30, 2023, current liabilities included accounts payable of $0.3 million, comprised primarily of expenses related to legal fees and patent fees of $0.2 million and clinical trial expenses of $0.1 million. As of December 31, 2022, current liabilities included accounts payable of $0.7 million, comprised primarily of expenses related to drug manufacturing, development and testing services of $0.6 million and legal and patent fees of $0.1 million.

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration